Dopamine, Oxidative Stress and Protein-Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases

Angew Chem Int Ed Engl. 2019 May 13;58(20):6512-6527. doi: 10.1002/anie.201811122. Epub 2019 Mar 21.

Abstract

Dopamine (DA) is the most important catecholamine in the brain, as it is the most abundant and the precursor of other neurotransmitters. Degeneration of nigrostriatal neurons of substantia nigra pars compacta in Parkinson's disease represents the best-studied link between DA neurotransmission and neuropathology. Catecholamines are reactive molecules that are handled through complex control and transport systems. Under normal conditions, small amounts of cytosolic DA are converted to neuromelanin in a stepwise process involving melanization of peptides and proteins. However, excessive cytosolic or extraneuronal DA can give rise to nonselective protein modifications. These reactions involve DA oxidation to quinone species and depend on the presence of redox-active transition metal ions such as iron and copper. Other oxidized DA metabolites likely participate in post-translational protein modification. Thus, protein-quinone modification is a heterogeneous process involving multiple DA-derived residues that produce structural and conformational changes of proteins and can lead to aggregation and inactivation of the modified proteins.

Keywords: Parkinson's disease; dopamine; neurodegeneration; neuromelanin; oxidative stress.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Dopamine / pharmacology
  • Dopamine / therapeutic use*
  • Humans
  • Neurodegenerative Diseases / drug therapy*
  • Oxidative Stress
  • Parkinson Disease / drug therapy*
  • Quinones / pharmacology
  • Quinones / therapeutic use*

Substances

  • Quinones
  • Dopamine